QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.

For more information, contact [email protected]. All ELI students from a country that has been identified as high-risk must be tested for Tuberculosis using the Quantiferon test before coming to ...

QIAGEN’s leading TB blood test, QuantiFERON-TB Gold Plus, remains crucial in detecting latent tuberculosis infection, aiding in breaking the cycle of disease transmission. QIAGEN’s TB Tests in ...

International students must have a QFT (Quantiferon blood test) or T-Spot (not PPD) with a negative result. This test must be completed in the United States and no more than three months before ...

The patent, among several owned by QIAGEN that protect the QuantiFERON technology, encompasses significant innovations in the QuantiFERON-TB Gold Plus, which is employed worldwide for tuberculosis ...

The QuantiFERON test delivered its sixth consecutive quarter of sales above $100 million, supported by solid demand from conversion gains against the tuberculin skin test in all regions.

T-Spot Lab Test, or Quantiferon Gold Lab Test. These health forms are required before moving into residence halls and starting classes at Keene State College. Health forms are due on June 1, 2022 for ...

This patent, which is one of many held by QIAGEN protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection.